ArticleJournal of migration and health2026
Design and results of a pilot community screening strategy for hepatitis B and hepatitis C to promote early access to treatment among migrant populations from high-prevalence countries residing in Catalonia (MiCatC).
Article in Journal of migration and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The elimination of hepatitis C virus (HCV) and hepatitis B virus (HBV) requires strategies to overcome barriers associated with access to healthcare among migrants. The objective was to design and implement a community-screening-strategy (MiCat) for HBV and HCV among migrant populations from high-prevalence countries residing in Catalonia. Methodology: A pilot community-screening was conducted in religious sites, associations or community centres. A multidisciplinary team consisting of peer educators, community health agents, and nurses was established. interventions consisted of workshops pertaining to viral hepatitis, rapid tests featuring onsite results and the collection of dried blood samples for HCV RNA test if anti-HCV-positive result. HBsAg-positive and/or HCV-RNA-positive participants were contacted and referred for hepatology. Results: A total of 1,505 people (71% men; 68% Pakistani) were screened over 10 months. Of the total, 71% were long-term residents in Catalonia (>5 years). The history of exposure was more common among women. A total of individuals tested, 3% (95% CI 2.2-4.0) (n=44) were HBsAg-positive (91% men; 33% new diagnoses), 36.4% (n=16) referred to hepatology (33% women) and 2 treated; and a 3.3% (95% CI 2.42-4.28) (n=49) were anti-HCV-positive (84% men), of these 32.6% (n=16) were HCV-RNA-positive (1.06% viremia prevalence; all new diagnoses), 13 patients completed the treatment. Conclusions: MiCatC project was able to detect, link to care and treat migrant population from countries with high prevalence of HCV and/or HBV based on a multidisciplinary team including community assets. It is essential to include the gender perspective to ensure that migrant women with hepatitis can receive specialised care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.